REDWOOD CITY, Calif.--(BUSINESS WIRE)--A.P. Pharma, Inc. (NASDAQ:APPA), a specialty pharmaceutical company, today provided an update on the timing for the submission of the New Drug Application (NDA) for APF530, the company’s lead product, which is being developed for the treatment of chemotherapy-induced nausea and vomiting (CINV).
